Intellia Therapeutics Inc
NTLA
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
95.6% downsideOvervalued by 95.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.81 |
| Beta | 1.93 |
| Outstanding Shares | 118,490,000 |
Return
| Return on Equity | -63.55% |
|---|---|
| Return on Assets | -52.00% |
| Return on Invested Capital | -44.89% |
Valuation & Multiples
| P/E Ratio | -4.22 |
|---|---|
| PEG | 26.69 |
| Price to Sales | -13.02 |
| Price to Book Ratio | 2.6 |
| Enterprise Value to Revenue | -965.94 |
| Enterprise Value to EBIT | -4.98 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3744▼ 30.38% |
|---|---|
| Total Calls | 3,932,912▲ 33.20% |
| Total Puts | 1,472,300▼ 26.47% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.88%▲ 7.27% |
|---|---|
| Total Invested | $1.41B▲ 50.64% |
| Investors Holding | 3180% |
ESG Score
No data
About Intellia Therapeutics Inc
211 employees
CEO: John Leonard Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...
Relevant Senate Committees
This committee's analysis and 'revenue estimates' are crucial for all tax legislation, directly influencing corporate tax structures, R&D capital investment credits, and the overall tax burden on a research-intensive company like Intellia Therapeutics.
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy, R&D credits, and Medicare pricing (influencing drug reimbursement) directly impact Intellia's profitability and market valuation.
This committee directly regulates the FDA and NIH, which are central to drug approval processes and research funding, making it a primary driver of stock performance in the pharmaceutical and biotech sectors.
This committee's oversight of antitrust laws and, crucially, intellectual property, is vital for a biotechnology company like Intellia, which relies heavily on patents for its CRISPR gene editing technology. It influences M&A and competition directly.